Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis

Acta Ophthalmologica Scandinavica

Volumn 81, Issue 4, 2003, Pages 378-382

  Yaylali, Volkan ^a   Demirlenk, Ibrahim ^a   Tatlipinar, Sinan ^a   Özbay, Davut ^a   Esme, Arif ^a   Yildirim, Cem ^a   Özden, Serap ^a  

^a PAMUKKALE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Ketorolac; Ocular allergy; Olopatadine; Seasonal allergic conjunctivitis

Indexed keywords

ANTAZOLINE; ANTIHISTAMINIC AGENT; CROMOGLYCATE DISODIUM; HISTAMINE H1 RECEPTOR ANTAGONIST; KETOROLAC TROMETAMOL; NAPHAZOLINE; NONSTEROID ANTIINFLAMMATORY AGENT; OLOPATADINE; PLACEBO; TEARS NATURALE; TEARS NATURALE II; VASOCONSTRICTOR AGENT;

ADULT; ALLERGIC CONJUNCTIVITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; LACRIMATION; MALE; MUCUS SECRETION; OCULAR PRURITUS; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; VISUAL SYSTEM PARAMETERS;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CONJUNCTIVA; CONJUNCTIVITIS, ALLERGIC; DIBENZOXEPINS; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; HYPEREMIA; KETOROLAC TROMETHAMINE; MALE; OPHTHALMIC SOLUTIONS; THERAPEUTIC EQUIVALENCY;

EID: 0042672615     PISSN: 13953907     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0420.2003.00079.x     Document Type: Article

References (11)

1. Abelson MB (1998): Evaluation of olopatadine, a new ophthalmic agent with dual activity, using the conjunctival allergen challenge model. Ann Allergy Asthma Immunol 81: 211-218.
2. Abelson MB & Schaefer K (1993): Conjunctivitis of allergic origin: immunological mechanisms and current approaches to therapy. Surv Ophthalmol 38: 115-132.
3. Abelson MB & Spitalny L (1998): Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine a new ophthalmic antiallergic agent with dual activity. Am J Ophthalmol 125: 797-804.
4. Ballas Z, Blumenthal M, Tinkelman DG, Kriz R & Rupp G (1993): Clinical evaluation of ketorolac tromethamine 0.5% ophthalmic solution for the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol 38: 141-148.
5. Berdy GJ, Abelson MB, George MA, Smith LM & Giovanni RL (1991): Allergic conjunctivitis: a survey of new antihistamines. J Ocul Pharmacol 7: 313-324.
6. Deschenes J, Discepola M & Abelson M (1999): Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model. Acta Ophthalmol Scand 77: 47-52.
7. Sharif NA, Xu SX, Miller ST, Gamache DA & Yanni JM (1996): Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases. J Pharmacol Exp Ther 278: 1252-1261.
8. Tinkelman DG, Rupp G, Kaufman H, Pugely J & Schultz N (1993): Double-masked, paired-comparison clinical study of ketorolac 0.5% ophthalmic solution compared with placebo eye drops in the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol 38: 133-140.
9. 1 receptors in the human ocular surface. [ARVO Abstracts.] Invest Ophthalmol Vis Sci 20: 32.
10. Woodward DF, Nieves L, Hawley SB, Joseph R, Merlino GF & Spada CS (1995): The pruritogenic and inflammatory effects of prostanoids in the conjunctiva. J Ocul Pharmacol Ther 11: 339-347.
11. Yanni JM, Stephens DJ, Miller ST et al. (1996): The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. J Ocular Pharmacol Ther 12: 389-400.